Galectin Therapeutics
GALT
63 hedge funds and large institutions have $21.5M invested in Galectin Therapeutics in 2014 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 12 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
3% less funds holding
Funds holding: 65 → 63 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
63% less capital invested
Capital invested by funds: $58.6M → $21.5M (-$37.1M)
72% less call options, than puts
Call options by funds: $326K | Put options by funds: $1.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$5.26M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$1.11M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$742K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$633K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.14M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.72M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$1.92M |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$581K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$467K |
GALT Hedge Fund Activity: Q3 2014 in Review
63 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2014, worth a combined $21.5M — down 63% from $58.6M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GALT and 10 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 22 added.
The largest buyer was Catalyst Capital Advisors, opening a new position worth an estimated $5.26M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.14M sold.
- 63 institutional investors held Galectin Therapeutics (GALT) as of Q3 2014, down from 65 in Q2 2014.
- Funds reported $21.5M of Galectin Therapeutics stock for Q3 2014, down 63% quarter-over-quarter.
- 10 funds opened new Galectin Therapeutics positions in Q3 2014 and 12 closed out, a net change of -2 holders.
- The largest Galectin Therapeutics buyer in Q3 2014 was Catalyst Capital Advisors, an estimated $5.26M added.
- The largest Galectin Therapeutics seller in Q3 2014 was Baker Bros. Advisors, an estimated $4.14M sold.
Based on aggregated 13F filings for Q3 2014.